ACG Education Universe - An online learning resource from the American College of Gastroenterology

It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments.

The vast majority of the material presented in the ACG Educational Universe has previously been presented in lecture or other learning format, and author disclosure information reflects the content and format for disclosure provided by the presenter as of the date that his/her material was presented and captured electronically, and in compliance with ACG policies and ACCME requirements in effect as of that date of presentation. Author and planner conflicts were identified and resolved in accordance with ACG’s Policies and Procedures on Identifying and Resolving Conflicts of Interest.

Unapproved 'Off-Label' Usage Policy

If any unapproved or off-label use of a product is to be referenced in a CME program presentation, the faculty member shall be required to disclose that the product is either investigational or it is not labeled for the usage being discussed.

Universe Editorial Board

It is the role of the Editors to assist with the strategic direction of the ACG Education Universe, assist with decisions relating to content review and selection, identifying and completing key areas where content and evaluation questions are needed, analysis of evaluations and user feedback, and generating ideas for further developments and enhancements to the Universe.

Editors

David A. Johnson, MD, FACG
Advisory Board: Bovie, Centocor, MedScape, JWatch Gastroenterology
Board of Directors: CRH Medical
Consultant:  Centocor, ICON, Ironwood, Roche/Genentech, Takeda
Research Grant: AstraZeneca
Speaker's Bureau: Takeda
Stockholder: Bovie, CRH Medical, GI View

Philip O. Katz, MD, FACG
Board of Directors: Esophageal Cancer Action Network
Consultant: Ferring, Ironwood, Medscape, Pfizer Consumer, Takeda
Royalties: ABIM
Speaker's Bureau: Takeda

Brooks D. Cash, MD, FACG
Consultant: Ironwood, Salix, Sucampo, Takeda
Speaker's Bureau: Ironwood, Salix, Takeda

Kenneth R. DeVault, MD, FACG
Consultant: Forest Labs, Given

Seth Gross, MD, FACG
Advisory Board: CDX Diagnostics
Consultant: CSA, Olympus
Speaker’s Bureau: Boston Scientific, Olympus
Stockholder: CSA

David T. Rubin, MD, FACG
Advisory Board: CCFA
Consultant: Abbott, Accordant Health, Elan Pharmaceuticals, Given Imaging, Janssen, Pfizer, Prometheus Laboratories, Salix Pharmaceuticals, Santarus Pharmaceuticals, Shire Pharmaceuticals, Takeda Pharmaceuticals, UCB Pharma
Research Support: Abbott, Elan Pharmaceuticals, Procter and Gamble/Warner Chilcott, Prometheus Laboratories, Shire Pharmaceuticals
Board of Directors/Employee: Cornerstones Health Inc.

Mitchell L. Shiffman, MD, FACG
Advisory Board: Abbott, Bayer, Genentech/Roche, Gilead, Globeimmune, GSK, Janssen, Merck,  Novartis, Salix, Vertex
Research Support: Abbott, Anadys, Conatus, Genentech/Roche, Gilead, Globeimmune, Idenix, Inhibitex, Intercept, Merck/Schering-Plough, Mochida, Novartis, Zymogenetics/BMS
Speaker's Bureau: Bayer, Bristol Myers-Squibb, Genentech/Roche, Gilead, Merck, Salix, Vertex